XTalks

NOVEMBER 12, 2024

Pneumonia is a lung infection that can be caused by viruses, bacteria or fungi and can result in millions of hospitalizations and deaths annually. These antibiotics target bacteria through mechanisms distinct from traditional antibiotics, thus helping to reduce the impact of resistant strains.

Bacteria 110

Bacteria Life Science Vaccine Vaccination 110

XTalks

DECEMBER 17, 2021

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Life Science 98

Life Science Vaccine Vaccination Trials 98

XTalks

AUGUST 26, 2020

Increasing research into the gut microbiome has revealed new and emerging roles for the ‘good bacteria’ in our bodies, with the latest being a new study that shows how they can help the immune system attack cancer cells. The findings were published in the journal Science.

Bacteria 52

Bacteria Research Immune Response Scientist 52

XTalks

AUGUST 26, 2020

Macrophages are white blood cells that specialize in the detection, phagocytosis and destruction of bacteria and other harmful organisms. In other words, when fighting bacteria, the macrophages are programmed to be pro-inflammatory. However, when they are programmed to be anti-inflammatory, they can help decrease inflammation.

Bacteria 105

Bacteria Immune Response Protein Medicine 105

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccine Vaccination Immune Response 89

XTalks

JUNE 21, 2024

According to a November 2023 readout, Capvaxive also elicited superior immune responses for ten of the 11 serotypes not covered by Prevnar 20. Related: Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from Merck – Xtalks Life Science Podcast Ep.

FDA Approval 108

FDA Approval Vaccine Vaccination Life Science 108

XTalks

JANUARY 20, 2021

While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.

Immune Response 52

Immune Response Research Allergies Protein 52